Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Targeted Drug Delivery Using Nanobodies to Deliver Effective Molecules to Breast Cancer Cells: The Most Attractive Application of Nanobodies Publisher



Abdolvahab MH1 ; Karimi P1 ; Mohajeri N1 ; Abedini M1 ; Zare H1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Source: Cancer Cell International Published:2024


Abstract

Targeted drug delivery is one of the attractive ways in which cancer treatment can significantly reduce side effects. In the last two decades, the use of antibodies as a tool for accurate detection of cancer has been noted. On the other hand, the binding of drugs and carriers containing drugs to the specific antibodies of cancer cells can specifically target only these cells. However, the use of whole antibodies brings challenges, including their large size, the complexity of conjugation, the high cost of production, and the creation of immunogenic reactions in the body. The use of nanobodies, or VHHs, which are a small part of camel heavy chain antibodies, is very popular due to their small size, high craftsmanship, and low production cost. In this article, in addition to a brief overview of the structure and characteristics of nanobodies, the use of this molecule in the targeted drug delivery of breast cancer has been reviewed. © The Author(s) 2024.
Other Related Docs
11. Novel Trastuzumab-Dm1 Conjugate: Synthesis and Bio-Evaluation, Journal of Cellular Physiology (2019)
18. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment, Regenerative Engineering and Translational Medicine (2024)
19. Emerging Immunologic Approaches As Cancer Anti-Angiogenic Therapies, Clinical and Translational Oncology (2025)
20. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)